Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 7/20 | 0.42 |
| ▸ | CNR1 | P21554 | 4/20 | 0.42 |
| ▸ | MLYCD | O95822 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9891808 | 0.85 | ALDH1A1 (0.67) | MAPK14ALDH1A1CNR2CNR1 | |
| SCHEMBL10171265 | 0.84 | ALDH1A1 (0.53) | MAPK14ALDH1A1CNR2CNR1 | |
| SCHEMBL8764313 | 0.83 | EPHX2 (0.53) | EPHX2MAPK14ALDH1A1IDO1CNR2 | |
| SCHEMBL9891815 | 0.81 | CNR2 (0.54) | MAPK14ALDH1A1CNR2CNR1 | |
| SCHEMBL12566646 | 0.81 | ALDH1A1 (0.50) | EPHX2MAPK14ALDH1A1CNR2CNR1 | |
| SCHEMBL13413814 | 0.81 | ALDH1A1 (0.50) | EPHX2MAPK14ALDH1A1CNR2CNR1 | |
| SCHEMBL14693072 | 0.81 | ALDH1A1 (0.50) | MAPK14ALDH1A1CNR2CNR1 | |
| SCHEMBL9891522 | 0.81 | ALDH1A1 (0.53) | EPHX2MAPK14ALDH1A1IDO1CNR2 | |
| SCHEMBL4284384 | 0.80 | EPHX2 (0.53) | EPHX2MAPK14ALDH1A1IDO1CNR2 | |
| SCHEMBL9892898 | 0.79 | EPHX2 (0.50) | EPHX2MAPK14ALDH1A1IDO1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | EPHX2 2014/4885MAPK14 1949/4885ALDH1A1 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.